Easton Pharmaceuticals Announces Preparations For North American Product(s) Launch

TORONTO, ON--(Marketwired - September 15, 2014) - Easton Pharmaceuticals (OTC: EAPH) Announces it has finalized and prepares for the launch of 3 initial OTC therapeutic products and other additional products for a marketing and sales launch.

As announced, Easton has previously received all required ingredients and has readied 3 of its main OTC therapeutic products which are VIORRA TM, SKIN RENOU HA, and KENESTRIN GEL. The 3 products will be made immediately available once packaging is delivered which involves containers and labeling. Included with the 3 initial Easton products are an additional 3 cosmetic products as a result of an agreement with a Toronto, Canada based manufacturer who will manufacture and supply the U.S. and Canadian markets. The line of products will be formally announced in the next few short weeks which is expected to be in conjunction with a marketing plan and partner who have been in discussions with the company over the past month for U.S. and Canadian distribution. The new marketing partner will be replacing the previous agreement signed with Global Links (OTC: GLCO) following Easton’s termination of the agreement originally signed in May of 2014.

The missing packaging and labeling component is only expected to take 2 weeks for completion. Products are expected to be available for sale within the next 30 to 45 days in preparation for the upcoming Christmas buying season on Easton’s website as well as multiple distributors as part of a comprehensive marketing strategy. Full details to be made shortly available. The initial products being launched, VIORRA TM, SKIN RENOU HA, and KENESTRIN GEL are expected to command a lucrative minimum gross margin of 40-50% at a wholesale level, which is considered very conservative. Detailed retail pricing will be announced on launch date.

VIORRA ™ = (Will service a broad female market including a growing ageing female population, but can also be utilized by younger woman to assist in naturally treating FSAD and lack of lubricity, a condition affecting millions of women of different ages. )

SKIN RENOU HA = ( A product to service the multi billion dollar anti wrinkle cosmetic industry which utilizes the company’s proprietary and patented transdermal delivery matrix to deliver Hyaluronic Acid and other active ingredients to treat wrinkles and ageing. )

KENESTRIN GEL = ( A product to help treat the multi billion dollar Rheumatoid Arthritis industry which affects people of all ages. The products main active ingredient is Hyaluronic Acid which acts as a cushion and lubricant in joints and other tissues which is applied utilizing the company’s patented transdermal delivery matrix. )

Easton will continue to utilize BMV Medica for its distribution of the same products in Mexico and Latin American markets and will use products manufactured in Canada for the short term to supply the Mexican and Latin American market until a final agreement is reached with a Mexican manufacturer which Dr. Daniel Bag and BMV has stated is close to finalization.

Carla Pepe, CEO of Easton Pharmaceuticals, commented “Although the launch of Viorra and our other OTC therapeutic products have recently taken a back seat to our medical marijuana initiatives, the company is quickly moving towards the launch of these products to take advantage of the Christmas shopping season and to demonstrate our commitment to this part of our business. We believe our marketing strategy which we expect to disclose very shortly will provide good exposure and resulting sales of all products being launched.”

In other developments, Easton reports that its Canadian Medical Marijuana initiative and its exclusive option with its partner regarding a letter to build it has received towards a medical marijuana national growers license is progressing. Two new medical marijuana licenses were recently issued by health Canada as they deal with a backlog and implement new security requirements for licensed producers and company’s who have received letters to build. Other news and updates soon expected regarding a possible Canadian dual listing and on its partnership with AMFIL Technologies.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues geared towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 50% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com

Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when used in the preceding of discussion, the words “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.